Issue 1/2012

Gpnmb/osteoactivin, an attractive target in cancer immunotherapy (1 — 5)

L. T. ZHOU, F. Y. LIU, Y. LI, Y. M. PENG, Y. H. LIU, J. LI

DOI: 10.4149/neo_2012_001

Differentiation pathways in carcinogenesis and in chemo- and radioresistance (6 — 17)

M. JANIKOVA, J. SKARDA

DOI: 10.4149/neo_2012_002

Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells (18 — 29)

L. L. DENG, Y. X. SHAO, H. F. LV, H. B. DENG, F. Z. LV

DOI: 10.4149/neo_2012_003

Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma (30 — 37)

M. ADAMKOV, K. KAJO, D. VYBOHOVA, J. KRAJCOVIC, F. STULLER, J. RAJCANI

DOI: 10.4149/neo_2012_004

Gemcitabine and Cisplatin Combination Chemotherapy in Triple Negative Metastatic Breast Cancer Previously Treated with a Taxane/Anthracycline Chemotherapy; Multicenter Experience (38 — 42)

M. OZKAN, V. BERK, M. A. KAPLAN, M. BENEKLI, U. COSKUN, A. BILICI, M. GUMUS, N. ALKIS, F. DANE, N. Y. OZDEMIR, D. COLAK, M. DIKILITAS

DOI: 10.4149/neo_2012_005

The influence of neuropilin-1 silencing on semaphorin 3A and 3C activity in B16(F10) murine melanoma cells (43 — 51)

A. M. MAZUREK, M. OLBRYT

DOI: 10.4149/neo_2012_006

The Expression and Clinical Significance of pSTAT3, VEGF and VEGF-C in Pancreatic Adenocarcinoma (52 — 61)

C. HUANG, R. HUANG, W. CHANG, T. JIANG, K. HUANG, J. CAO, X. SUN, Z. QIU

DOI: 10.4149/neo_2012_007

Gentiana asclepiadea and Armoracia rusticana can modulate the adaptive response induced by zeocin in human lymphocytes (62 — 69)

A. HUDECOVA, K. HASPLOVA, L. KELLOVSKA, M. IKRENIOVA, E. MIADOKOVA, E. GALOVA, E. HORVATHOVA, D. VACULCIKOVA, F. GREGAN, M. DUSINSKA

DOI: 10.4149/neo_2012_01_008

Long-term trends in the development of the epidemiology of breast cancer in the Slovak and Czech Republic with reference to applied screening and international comparisons (70 — 78)

M. ONDRUSOVA, J. MUZIK, S. DURDIK, D. ONDRUS

DOI: 10.4149/neo_2012_009

Microsomal epoxide hydrolase polymorphisms, cigarette smoking and prostate cancer risk in the Slovak population (79 — 84)

M. KMETOVA SIVONOVA, D. DOBROTA, T. MATAKOVA, R. DUSENKA, S. GROBARCIKOVA, V. HABALA, J. SALAGOVIC, M. TAJTAKOVA, A. PIDANICOVA, L. VALANSKY, L. LACHVACS, J. KLIMENT, JR., V. NAGY, J. KLIMENT

DOI: 10.4149/neo_2012_010

Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status (85 — 91)

M. E. KRASTEVA, S. S. BOZHANOV, G. G. ANTOV, Z. I. GOSPODINOVA, S. G. ANGELOVA AND E. I. GEORGIEVA

DOI: 10.4149/neo_2012_011

Characterization of adrenal metastatic cancer using FDG PET/CT (92 — 99)

B. XU, J. GAO, L. CUI, H. WANG, Z. GUAN, S. YAO, Z. SHEN, J. TIAN

DOI: 10.4149/neo_2012_012

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer Patients Who Received Surgical Resection in China (100 — 104)

H. Y. LU, W. Y. SUN, B. CHEN, Y. P. ZHANG, J. F. CAI, D. SU, Z. WANG, Y. Q. ZHENG, S. L. MA

DOI: 10.4149/neo_2012_013

Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo (105 — 113)

W. YUAN, Z. CHEN, Z. CHEN, S. WU, J. GUO, J. GE, P. YANG, J. HUANG

DOI: 10.4149/neo_2012_014

Stereotactic radiotherapy (SBRT) as a sole or salvage therapy in non-small cell lung cancer patients (114 — 120)

T. DWORZECKI, A. IDASIAK, D. SYGUŁA, U. DWORZECKA, R. SUWIŃSKI

DOI: 10.4149/neo_2012_015